Beyond DNA repair: the novel immunological potential of PARP inhibitors.
![Thumbnail](/bitstream/handle/internal/3248/Beyond%20DNA%20repair%20the%20novel%20immunological%20potential%20of%20PARP%20inhibitors.pdf.jpg?sequence=37&isAllowed=y)
View/ Open
Date
2019-01-01ICR Author
Author
Chabanon, RM
Soria, J-C
Lord, CJ
Postel-Vinay, S
Type
Journal Article
Metadata
Show full item recordAbstract
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations, might mediate their therapeutic effects by potentiating anti-tumor immunity.
Collections
Research team
Gene Function
Language
eng
Date accepted
2019-02-18
License start date
2019-01
Citation
Molecular & cellular oncology, 2019, 6 (2), pp. 1585170 - ?
Publisher
TAYLOR & FRANCIS INC